GTx, Inc. (NASDAQ:GTXI) Files An 8-K Other Events
Item 8.01 Other Events.
On November16, 2016, GTx,Inc. issued a press release announcing
the achievement of the Stage 1 milestone for the 18 mg cohort of
its Phase 2 clinical trial of enobosarm (GTx-024) to treat women
with advanced, estrogen receptor positive, androgen receptor
positive breast cancer.
A copy of the press release is furnished as Exhibit99.1 to this
Current Report.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits.
|
ExhibitNo. |
|
Description |
|
99.1 |
Press Release issued by GTx,Inc. dated November16, 2016 |
About GTx, Inc. (NASDAQ:GTXI)
GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage. GTx, Inc. (NASDAQ:GTXI) Recent Trading Information
GTx, Inc. (NASDAQ:GTXI) closed its last trading session up +0.060 at 0.880 with 130,235 shares trading hands.
